However, topline results released by NovoNordisk stated that their two phase 3 trials investigating once-daily oral semaglutide in early-stage Alzheimers disease (clinical trial numbers NCT04777396 and NCT04777409) did not confirm the superiority of semaglutide versus placebo in reducing the progression of Alzheimers disease, as measured by the change in Clinical Dementia Rating Sum of Boxes score compared with baseline
35LeeWM, HynanLS, RossaroL,
2007, American College of Obstetricians & Gynecologists (US), 3 Wang Y, Sharma RK, Falcone T, Goldberg J, Agarwal A: Importance of reactive oxygen species in the peritoneal fluid of women with endometriosis or idiopathic infertility
PMID 15996001
Suspected adverse reactions can be reported through the MHRA Yellow Card Scheme
Certificate of Analysis (CoA) A legitimate supplier provides batch-specific HPLC and mass spectrometry data confirming purity, typically 98% for research-grade peptide